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Abstract
Background Allo-HSCT has been shown to increase survival and improve cure
in acute leukemia (AL). However, this procedure is accompanied by high rates
of morbidity and mortality. Several risk scores based on conventional
statistical methods may aid decision regarding whom and how to perform
allo-HSCT, but these methods carry inherent limitations, which may lead to
sub-optimal candidate selection. Machine learning (ML) is a field in computer
science stemming from artificial intelligence and is part of the data mining
approach for data analysis. ML algorithms are commonly applied in
technological and commercial settings. They allow for coping with complex
data scenarios and thus may be suitable for outcome prediction in allo-HSCT.
With this background, and using a ML prediction method- the alternating
decision tree (ADT) algorithm, we developed an interpretable model for
overall mortality (OM) and treatment-related mortality (TRM) at day +100 after
allo-HSCT in AL.
Patients and Methods 28,995 adult allo-HSCT recipients from the registry of
the ALWP of EBMT were analyzed. Twenty two variables were available
including year of transplant (range, 2000-2011), diagnosis (Acute Myeloid
Leukemia and Acute Lymphoblastic Leukemia), disease status, Karnofsky
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performance status, conditioning regimen (myeloablative or reduced-
intensity conditioning), graft type (peripheral blood, bone marrow or cord
blood), donor and recipient HLA compatibility, CMV serostatus, GVHD
prophylaxis regimens, etc. Per study definitions, the primary outcomes to be
predicted were OM and TRM at day +100 days after allo-HSCT. The complete
dataset was split into 3 sets: training set (n=11,600), testing set (n=8,688)
and validation set (n=8,707). The ADT prediction model was tested and
optimized according to the first 2 subgroups and validated on the last one.
Output from the ADT model, included variables selection with assigned
scores in a tree-based structure and area under the ROC curve (AUC), a
measure for model discrimination
Results Each of the ADT models selected 12 out 22 variables for prediction
of OM and TRM at day +100. Ten variables were mutual for both prediction
models, although different weights were assigned. These included: age,
diagnosis, disease status, Karnofsky performance status (all at time of
transplant), donor-recipient HLA-matching, number of transplants in each
center per year, year of transplant, conditioning regimen and the donor's and
patient's CMV serostatus. Variables selected exclusively by the OM prediction
model were graft type and donor-patient CMV serostatus match, whereas the
TRM model selected time from diagnosis to transplant and donor-recipient
sex match. Applying the models on the validation set yielded AUCs of 0.701
(95% confidence interval [CI] 0.691-0.710) for OM prediction and 0.67 (95%
[CI] 0.66-0.68) for TRM. The ADT prediction models assigned scores
correlating with patient outcome. Patients in each of the validation sets were
grouped according to their score range and the prediction success. A Higher
score was correlated with higher rate of the measured outcome in both





No related articles found.
Articles by Labopin, M.
Articles by Mothy, M.
Articles by Labopin, M.
Articles by Mothy, M.
-
-
15/11/15 14:29Blood Journal | Prediction Of Allogeneic Hematopoietic Stem Ce…ta Set of The Acute Leukemia Working Party (ALWP) Of The EBMT
Page 3 sur 3http://www.bloodjournal.org/content/122/21/409.full.pdf
Download figure | Open in new tab | Download powerpointFigure 2
Conclusions We present two new models, based on the ADT ML algorithm,
for prediction of OM and TRM at day +100 after allo-HSCT. The models are
robust as they rely on a high number of samples and a large validation set.
As shown in the figures, higher scores correlated with a poorer outcome,
reaching more than 50% mortality for a score range of 5.76-7 in the OM
prediction model. The AUC performance measure was better for OM than
TRM, possibly due to a higher event rate in former, making it easier to
predict. Improving the predictive ability will probably necessitate evaluation
of more variables, as the limitation of the maximal predictive performance is
most likely in the information gained from the variables and not from the
sample size or algorithm used. This is currently under progress, especially
combination with other risk scores linked to comorbidities.
In summary, our models can aid candidate selection for allo-HSCT, by
providing a measurable score that correlates with transplant success.
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